Emerging treatments
T-cell receptor therapy shows promise in multiple myeloma. Bagcchi S. Lancet Oncol. 2015 Jul 23. pii: S1470-2045(15)00191-6. doi: 10.1016/S1470-2045(15)00191-6. [Epub ahead of print]. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Rapoport AP et al. Nat Med. 2015 Jul 20. doi: 10.1038/nm.3910. [Epub ahead of print]. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple…
Details